Overview of BioArctic's Upcoming Q3 Report Presentation
BioArctic AB (publ) is excited to announce its upcoming presentation of the third quarter report, set to take place on November 14, 2024. This event will provide a comprehensive overview of the company’s financial performance and strategic direction during the period from July to September 2024. The report will be released early in the morning, at 08:00 a.m. CET, allowing stakeholders ample time to review the materials before the presentation.
Details of the Audiocast and Teleconference
Simultaneously with the release of the report, BioArctic invites investors, analysts, and media representatives to participate in a live audiocast and teleconference at 09:30 CET. Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, will lead the presentation, providing insights and commentary on BioArctic's recent developments and performance metrics.
How to Participate
For those interested in joining the presentation via webcast, a link will be provided on BioArctic's corporate website. During the webcast, participants will have the opportunity to submit written questions, making the event interactive and engaging. This format promotes a seamless dialogue between the company’s leadership and stakeholders.
Teleconference Registration
Alternatively, individuals who prefer to engage through a teleconference setup can register ahead of time. Upon registration, participants will receive phone numbers and a unique conference ID to access the presentation. This option allows for direct verbal questioning, enhancing the engagement during the Q&A session following the presentation.
Availability of the Webcast
The audiocast will also be available on-demand through BioArctic's website post-presentation. This ensures that anyone unable to attend the live session can catch up on the insights shared during the event. The on-demand option facilitates continuous engagement with the company's updates.
Contact Information
For more details regarding the event, Oskar Bosson, VP of Communications and Investor Relations at BioArctic, is available to assist. He's committed to ensuring that all inquiries are addressed promptly. You can reach out via the contact methods provided in the announcements or within the corporate contacts section.
Get to Know BioArctic AB
BioArctic AB is a pioneering Swedish biopharmaceutical company specializing in innovative treatments for neurodegenerative diseases. One of its significant achievements is the development of Leqembi® (lecanemab), recognized globally as a breakthrough drug that slows the progression of early Alzheimer's disease. Collaborating with Eisai, BioArctic focuses on bringing life-changing solutions to patients. In addition to Leqembi, the company is actively engaged in research for treatments targeting Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS) using their unique BrainTransporter™ technology. This technology highlights BioArctic's dedication to advancing health and improving therapeutic outcomes.
BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap, reflecting its strong market presence and investor confidence.
Frequently Asked Questions
What is the date and time of BioArctic's Q3 report presentation?
The presentation will occur on November 14, 2024, at 09:30 a.m. CET.
Who will be presenting during the event?
Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, will present and comment on the report.
Can I participate in the presentation remotely?
Yes, participants can join via a webcast. Registration is required for teleconference participation.
What topics will be covered during the Q3 presentation?
The presentation will cover BioArctic's financial performance and insights into their ongoing projects and strategies.
How can I contact BioArctic for further information?
You can reach out to Oskar Bosson, VP of Communications and Investor Relations, for any inquiries.
